QUVIVIQ

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug QUVIVIQ contains one active pharmaceutical ingredient (API):

1	Daridorexant UNII 9X9581N56R - DARIDOREXANT HYDROCHLORIDE
	Daridorexant is a dual orexin receptor antagonist, acting on both orexin 1 and orexin 2 receptors and equipotent on both. The orexin neuropeptides (orexin A and orexin B) act on orexin receptors to promote wakefulness. Daridorexant antagonises the activation of orexin receptors by the orexin neuropeptides and consequently decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages.
	Read more about Daridorexant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QUVIVIQ Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CM	Other hypnotics and sedatives	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives
Discover more medicines within N05CM

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1882470, 1882481, 1882492, 1882504
ES	Centro de información online de medicamentos de la AEMPS	1221638002, 1221638003
IT	Agenzia del Farmaco	050050018, 050050020, 050050032, 050050044, 050050057, 050050069
LT	Valstybinė vaistų kontrolės tarnyba	1094658, 1094659, 1094660, 1094661, 1094873, 1094874
PL	Rejestru Produktów Leczniczych	100468984, 100468991
US	FDA, National Drug Code	80491-7825, 80491-7850